Drug delivery to the brain: How can nanoencapsulated statins be used in the clinic?
- Publication Type:
- Journal Article
- Therapeutic Delivery, 2017, 8 (8), pp. 625 - 631
- Issue Date:
Files in This Item:
|s1-ln747880988320092-1939656818Hwf-91030089IdV134014367747880PDF_HI0001.pdf||Submitted Version||303.7 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
The embargo period expires on 1 Aug 2018
© 2017 Future Science Ltd. Statins are used for the primary and secondary prevention of cardiovascular disease by inhibiting cholesterol synthesis in the liver. Statins have also noncholesterol-related effects, called pleiotropic effects, which arise from statins' anti-inflammatory, immunomodulatory and antioxidant properties. These effects are especially attractive for the treatment of various brain diseases ranging from stroke to neurodegenerative diseases. Still, low brain concentrations after oral drug administration hinder the clinical application of statins in these pathologies. Pharmaceutical nanotechnologies may offer a solution to this problem, as local or targeted delivery of nanoencapsulated statins may increase brain availability. This special report rapidly summarizes the potential of statins in the treatment of brain diseases and the pharmaceutical nanotechnologies that could provide a viable approach to enable these indications.
Please use this identifier to cite or link to this item: